NEW YORK (GenomeWeb News) – BG Medicine has been warned by Nasdaq that it fails to meet another requirement to remain listing on the Nasdaq Global Market, the company said in a document filed with the US Securities and Exchange Commission on Wednesday.

In a Nov. 22 letter from Nasdaq, BG Medicine was told that its publicly held shares closed below the minimum $15 million threshold for the preceding 30 consecutive business days, putting the company at risk of being delisted. BG Medicine has until May 21, 2014 to regain compliance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.